drugset / Trial / NCT06501924
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Phase 3
Not yet recruiting
516 enrolled
Applied Biology, Inc.
Daniel Alain, Inc. · collabFollea International Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
Timeline
- Start
- 2025-01-15
- Primary completion
- 2025-10-17
- Completion
- 2025-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-002 | Unknown | — | Topical |
| Comparator | Minoxidil | Small molecule | 5 % | Topical |